Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?

Jeffrey Shevach, Matthew R. Sydes, Maha Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

There has been significant progress in managing men with metastatic hormone-sensitive prostate cancer with unprecedented prolongation of overall survival with therapy intensification. Critical to this progress was maximizing the antitumor strategy that is based on continuous androgen deprivation combined with docetaxel or abiraterone + prednisone. Intermittent androgen deprivation as previously tested has not lived up to the expectations and hence is not considered an optimal standard of care option. As therapy is being intensified and patients are living longer, its role moving forward should be critically evaluated in prospective well-designed clinical trials.

Original languageEnglish (US)
Pages (from-to)125-133
Number of pages9
JournalEuropean Urology Focus
Volume5
Issue number2
DOIs
StatePublished - Mar 2019

Keywords

  • Intermittent androgen deprivation
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?'. Together they form a unique fingerprint.

Cite this